SAN DIEGO, May 23, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI) (http://www.apricusbio.com) today announced that Linda Smibert, Vice President, Business Development at the Company's NexMed, USA, Inc. subsidiary, will present at the Euro-Biotech Partnering Forum 2011 conference in Paris, France, on Tuesday, May 24th at 10:00 am CET.
Ms. Smibert's presentation will include an update of the Company's portfolio, and current worldwide licensing and commercialization efforts for Vitaros® for erectile dysfunction ("ED"), in our continual efforts to finalize a partnership for Canada and Europe, this year. In addition, Ms. Smibert will be giving one-to-one presentations on the Company's four later clinical-stage products, Femprox® for female sexual arousal disorder, MycoVa™ for onychomycosis, PrevOnco™ for liver cancer, and RayVa™ for Raynaud's phenomenon, in patients with systemic sclerosis. Mark Wilson, Vice President, NexACT® Technology Licensing, will join Ms. Smibert to focus on partnering the use of NexACT® Technology to pharmaceutical and biotechnology companies.
The Company has received approval for its Vitaros® product for ED in Canada, filed for approval for this product in the European Union through the Decentralized Procedure and received guidance from the Swiss regulatory authorities to file for approval in that country -- an approval that may permit the Company to receive additional approvals in other non-EU European countries. Apricus Bio is also planning to make initial filings for the product for ED in the MENA (Middle Eastern and North African) countries in 2011. In addition, Apricus Bio is in negotiations with various partners to license and commercialize Vitaros® for ED in Canada and certain European countries, in order to complement the partnerships for this product that the Company has already announced in the last six months. These include partnerships in Italy with Bracco SpA, in the Gulf Countries and certain countries in the Middle East with Elis Pharmaceuticals, and in Israel and the Palestinian Territories with the Neopharm Group.
"The Euro-Biotech Partnering Forum is an important meeting for Apricus Bio since it provides a centralized forum for us to continue partnership negotiations in a very condensed and focused mode," stated Dr. Bassam Damaj, President and Chief Executive Officer of Apricus Bio.
About Apricus Biosciences, Inc.
Apricus Bio, a San Diego based revenue-generating pharmaceutical company, has leveraged the flexibility of its clinically-validated NexACT® drug delivery technology to enable multi-route administration of new and improved compounds across numerous therapeutic classes.
Revenues and growth are driven from out-licensing of this technology for the development and commercialization of such compounds to pharmaceutical and biotechnology companies worldwide. In addition, the Company is seeking to monetize its existing product pipeline, including its first product, Vitaros®, approved in Canada for the treatment of erectile dysfunction, which is currently expected to be available on the Canadian market in 2011, as well as compounds in development from pre-clinical through Phase III, currently focused on Sexual Dysfunction, Oncology, Dermatology, Autoimmune, Pain, Anti-Infectives, Diabetes and Cosmeceuticals among others.
For further information on Apricus Bio, visit http://www.apricusbio.com and for information on its subsidiaries please visit www.nexmedusa.com or www.bio-quant.com. You can also receive information at http://twitter.com/apricusbio and http://facebook.com/apricusbio.
Apricus Bio's Forward-Looking Statement Safe Harbor
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, its ability to further development products and product candidates, to have its products such as Vitaros®, Femprox®, MycoVa™, PrevOnco™, and RayVa™ among others and product candidates approved by relevant regulatory authorities, to successfully commercialize such products and product candidates and to achieve its other development, commercialization and financial goals. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.